Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Fecal matter transplant
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
A '''fecal matter transplant''' or fecal microbiota transplant (FMT) is a therapy that involves the transfer of fecal waste from a healthy donor to the colon of a patient. It's most common use is in the treatment of recurrent [[clostridium difficile]] (C.diff) infections. Interest in fecal matter transplants has grown in those experiencing chronic gastrointestinal problems, including [[chronic fatigue syndrome]]. ==Methods== Fecal matter from a person with healthy [[Microbiome|gut flora]] is mixed with saline, strained, inserted into the recipient patient with via a colonoscopy, endoscopy, sigmoidoscopy, or enema in order to recolonize the ill person's bowels.<ref>{{Cite journal | last = Bakken | first = Johan S. | last2 = Borody | first2 = Thomas | last3 = Brandt | first3 = Lawrence J. | last4 = Brill | first4 = Joel V. | last5 = Demarco | first5 = Daniel C. | last6 = Franzos | first6 = Marc Alaric | last7 = Kelly | first7 = Colleen | last8 = Khoruts | first8 = Alexander | last9 = Louie | first9 = Thomas | date = 2011-12-01 | title = Treating Clostridium difficile Infection With Fecal Microbiota Transplantation | url =http://www.sciencedirect.com/science/article/pii/S1542356511008913|journal=Clinical Gastroenterology and Hepatology|volume=9|issue=12 | pages = 1044–1049|doi=10.1016/j.cgh.2011.08.014|issn=1542-3565}}</ref><ref>{{Cite web | url=http://thefecaltransplantfoundation.org/what-is-fecal-transplant/ | title = What is FMT? – The Fecal Transplant Foundation|language=en-US|access-date=2019-06-11}}</ref> It is recommended that the donor be someone close to the patient, with the first choice being a spouse or significant other, but other close friends, relatives, or a "universal donor" source may be warranted. The physician should ensure that the "universal donor" source employs rigorous screening and testing standards.<ref>{{Cite web | url=https://www.idsociety.org/public-health/emerging-clinical-issues/emerging-clinical-issues/fecal-microbiota-transplantation/ | title = Fecal Microbiota Transplantation | website = idsociety.org|language=en|access-date=2019-06-11}}</ref> Testing includes screening the donors’ blood for diseases such as [[HIV/AIDS|HIV]] and [[hepatitis]] and testing their stool for bacterial pathogens, [[Giardia lamblia|giardia]] and cryptosporidium, parasites, and [[clostridium difficile|C. difficile]].<ref>{{Cite web | url=https://scienceline.org/2011/11/fecal-transplants-the-scoop-on-therapeutic-poop/ | title = Fecal transplants: the scoop on therapeutic poop | date = 2011-11-15 | website = Scienceline|language=en-US|access-date=2019-06-11}}</ref> ==Evidence== ===Critique of Borody study using FMT for chronic fatigue syndrome=== A 2012 study by Borody, at el, using a variety of antibiotics followed by one to three fecal matter transplants (and in six patients an oral course of cultured bacteria), reported a 70% rate of improvement of sleep and "lethargy/fatigue" symptoms in [[Fukuda criteria|Fukuda]] CFS patients recruited from a clinic for digestive disorders.<ref name=":1">{{Cite journal | last = Borody | first = Thomas J | author-link = | last2 = Nowak | first2 = Anna | authorlink2 = | last3 = Finlayson | first3 = Sarah | date = Dec 2012 | title = The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy| url = https://search.informit.com.au/documentSummary;dn=119626231492520;res=IELHEA|journal=Journal of the Australasian College of Nutritional and Environmental Medicine|volume=31|issue=3 | pages = 3-8|quote=|via=}}</ref> The authors reported a 58% success rate at long term followup 15-20 years post-treatment, but only 12 patients (out of the original 60) were contacted at that point. Accordingly, the long-term followup results would not have been statistically significant. That study also neglected to use any objective outcome measurements, a control group was not included, and the symptoms used to determine a successful outcome regarding "CFS symptoms" did not account for physical limitations or many other fundamental ME/CFS symptoms. It is not clear how many symptoms were measured before and after treatment, hence it cannot be determined if any results were statistically significant. Furthermore, all patients were recruited from a clinic for digestive disorders, which would suggest that they were not typical ME/CFS patients. The recruitment criteria did not require that patients have the symptom of [[post-exertional malaise]], hence the results may not be applicable to ME/CFS patients meeting more stringent criteria. There was no study protocol published, and there is no explanation provided for the results first being published as a full paper fifteen years after the initial treatments took place. A conference poster abstract from 1995 indicates that other symptoms were tested at an earlier followup,<ref>{{Cite journal | last = Borody | first = TJ | author-link = | date = 1995 | title = Bacteriotherapy for Chronic Fatigue Syndrome – A long-term follow-up study | url = |journal=Proceedings of ACMA Complementary Medicine Sydney 1995|volume=|issue=| pages=|quote=|via=}}</ref> but those symptoms are not reported or discussed in the 2012 long-term followup, which may indicate that the treatment was less successful than reported. The poster abstract does not appear to have been published, and the full long-term followup was published in an obscure online journal with no apparent peer review process. This study has not been replicated, and no other studies for FMT and ME/CFS have been conducted. Accordingly, the existing evidence base in favor of this therapy is very weak. ===RESTORE-ME clinical trial=== A feasibility study for a clinical trial of FMT for patients with ME/CFS is in progress in the UK, with support and funding from the charity [[Invest in ME Research]].<ref name="quadram-trial">https://quadram.ac.uk/restore-me-trial-event/</ref> The study is led by [[Simon Carding]] or the [[Quadram Institute]]. The RESTORE-ME clinical trial aims to find out if FMT will restore a healthy gut microbiome in ME patients, and to find out if this improves physical and mental health of those with ME.<ref name="Carding2020-slides">{{Cite web | url=https://quadram.ac.uk/wp-content/uploads/2020/02/ME-Public-Event-2020-all-slides-v8-final-for-website.pdf | title=Gut Microbes, FMT and ME | last = Carding | first = Simon | author-link = Simon Carding|website=Quadram Institute | date = Feb 2020}}</ref> This is a double-blinded, randomized controlled trial in phase IIb, and involves 160 mildly/moderately ill ME patients.<ref name="Carding2020-slides" /> It was expected to begin in September 2020, but this has been altered due to the COVID-19 pandemic.<ref name="Carding2020-slides" /> == Risk == The [[U.S. Food and Drug Administration]] (FDA) has warned of the possiblity that FMT may cause serious or life threatening infections, including bacterial and viral infections, with at least one fatal infection reported.<ref name="FDA-sar2019">{{Cite web | url=https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse | title = Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms | last = | first = | authorlink = | date = Jun 13, 2019 | website = U.S. Food & Drug Administration|archive-url=|archive-date=|url-status=|access-date=Jun 15, 2019}}</ref><ref name="FDA-covid19-2020">{{Cite web | url=https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-regarding-additional-safety-protections-pertaining | title = Fecal Microbiota for Transplantation: Safety Alert - Regarding Additional Safety Protections Pertaining to SARS-CoV-2 and COVID-19 | last = | first = | authorlink = | date = Mar 23, 2020 | website = U.S. Food & Drug Administration|archive-url=|archive-date=|url-status=|access-date=Apr 17, 2020}}</ref> === Multi-drug resistant organisms === The FDA reported two cases in immunocompromised adults of bacterial infections with multi-drug resistant organisms (MDROs) that occurred due to use of investigational FMT.<ref name="FDA-sar2019" /> In both cases, the FMT was prepared from stool obtained from the same donor, and the recipients became infected with extended-spectrum beta-lactamase (ESBL)-producing [[Escherichia coli]] (E.coli), which was later found to be present in donor stool.<ref name="FDA-sar2019" /> One of the recipients died.<ref name="FDA-sar2019" /> As a result of these cases, the FDA has determined that donor screening must include questions that address risk factors for MDROs and donor stools must be tested for MDROs.<ref name="FDA-sar2019" /> ===SARS-CoV-2 and COVID-19=== The [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]] RNA and/or virus that causes [[COVID-19]] has been found in stool samples, suggesting it could be transmitted by FMT.<ref name="FDA-sar2019" /> The FDA has stated the risk is unknown and advised donor screening for SARS-CoV-2 and testing donors or donor stools be screened, and informing patients of the potential risk.<ref name="FDA-sar2019" /> == Availability == ===United States=== FMT is regulated by the [[U.S. Food and Drug Administration]] (FDA), which has not approved it for any use.<ref>{{Cite web | url=https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-about-potential-risk-serious-infections-caused-multi-drug-resistant-organisms | title = FDA In Brief: FDA warns about potential risk of serious infections caused by multi-drug resistant organisms related to the investigational use of Fecal Microbiota for Transplantation | last = | first = | authorlink = | date = June 13, 2019 | website = U.S. Food & Drug Administration|archive-url=|archive-date=|url-status=|access-date=June 15, 2019}}</ref> The [[FDA]] has classified human stool as a biological agent and determined that its use in fecal matter transplantation (FMT) therapy and other research should be regulated to ensure patient safety. In order for a physician or researcher to use FMT in a clinical trial or to treat any condition other than reoccurring, antibiotic-resistant [[clostridium difficile]] infections, an investigational new drug (IND) permit is required.<ref>{{Cite web | url=https://www.idsociety.org/public-health/emerging-clinical-issues/emerging-clinical-issues/fecal-microbiota-transplantation/ | title = Fecal Microbiota Transplantation | website = idsociety.org|language=en|access-date=2019-06-11}}</ref> ===United Kingdom=== In the [[United Kingdom|UK]], some clinics, such as the Taymount Clinic, Hertfordshire, England, offer FMT for a wide range of GI and chronic illnesses.<ref>{{Cite web | url=https://taymount.com/ | title = Gut Flora Transplants|website=Taymount Clinic|language=en-GB|access-date=2019-06-11}}</ref> ===Australia=== [[Australia]] has some of the most active FMT clinics, such as the Centre for Digestive Diseases in Sydney, under the direction of Thomas J. Borody, MD, PhD.<ref>{{Cite web | url=https://centrefordigestivediseases.com/ | title = The Centre for Digestive Diseases – The centre of excellence for gastroenerology|language=en-US|access-date=2019-06-11}}</ref> Dr Borody has conducted many FMT studies over the past 30 years on FMT, including studies assessing efficacy for chronic fatigue syndrome, although criticism regarding patient selection and follow-up have caused doubt on the study results. (Critique can be found in a section [[Fecal matter transplant#Study using FMT for chronic fatigue syndrome|below]].) Additionally Dr Paul Froomes, Melbourne, performs FMT.<ref>{{Cite web | url=http://www.drpaulfroomes.com.au/ | title = Home|website=Dr Paul Froomes - Consultant Gastroenterologist {{!}} Melbourne|language=en-US|access-date=2019-06-11}}</ref> ===Norway=== In 2017, the Research Council of [[Norway]] (Norges forskningsråd) announced undertaking a randomized controlled trial for use of fecal microbiota transplant in [[chronic fatigue syndrome]].<ref name=":0">{{Cite web | url=https://clinicaltrials.gov/ct2/show/NCT03691987 | title = The Comeback Study - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2019-06-11}}</ref> A randomized, placebo-controlled trial called "The Comeback" study is currently underway at the University Hospital of North Norway. Eighty ME/CFS patients will be followed up for 12 months after receiving either fecal microbiota transplantation (FMT) or a placebo. The trial will take many years to complete. Final results are expected in 2023.<ref name=":0" /> ==Home experimentation== The medical cautions and strict FDA regulation hasn't stopped people, especially those with GI illnesses, such as [[ulcerative colitis]] or [[irritable bowel syndrome]], from experimenting on their own with FMT. Recipes for do-it-yourself FMT are abundant online, including Dr. [[Sarah Myhill]]'s protocol, Probiotic Therapy Home Infusion Protocol.<ref>{{Cite web | url=http://www.drmyhill.co.uk/drmyhill/images/4/49/Home_Infusion_protocol.pdf | title=Probiotic Therapy Home Infusion Protocol | last = | first = | authorlink = | date = | website = |archive-url=|archive-date=|url-status=|access-date=2019-06-11}}</ref> DIY fecal transplants have been reported to potentially cause a condition called [[Small intestinal bacterial overgrowth]] (SIBO).<ref>{{Cite web | url=https://www.webmd.com/digestive-disorders/news/20151209/diy-fecal-transplant | title = The Rise of the Do-It-Yourself Fecal Transplant | last = Goodman | first = Brenda | last2 = MA|website=WebMD|language=en|access-date=2022-05-07}}</ref> ==Research studies== *2012, The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy<ref name=":1" /> *2013, High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients<ref>{{Cite journal | last = Frémont | first = Marc | authorlink = | last2 = Coomans | first2 = Danny | authorlink2 = | last3 = Massart | first3 = Sebastien | authorlink3 = | last4 = De Meirleir | first4 = Kenny | authorlink4 = Kenny De Meirleir | authorlink5 = | date = Aug 2013 | title = High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients |url =https://linkinghub.elsevier.com/retrieve/pii/S1075996413000929|journal=Anaerobe|language=en|volume=22|issue= | pages = 50–56|doi=10.1016/j.anaerobe.2013.06.002|quote=|via=}}</ref> *2016, Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders<ref>{{Cite journal | last = Evrensel | first = Alper | last2 = Ceylan | first2 = Mehmet Emin | date = 2016-08-31 | title = Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders |url =http://www.cpn.or.kr/journal/view.html?doi=10.9758/cpn.2016.14.3.231|journal=Clinical Psychopharmacology and Neuroscience|language=en|volume=14|issue=3 | pages = 231–237|doi=10.9758/cpn.2016.14.3.231|issn=1738-1088}}</ref> *2019, A retrospective outcome study of 42 patients with Chronic Fatigue Syndrome, 30 of whom had Irritable Bowel Syndrome. Half were treated with oral approaches, and half were treated with Faecal Microbiome Transplantation<ref>{{Cite journal | last = Kenyon | first = J.N. | author-link = | last2 = Coe | first2 = Shelly | authorlink2 = | last3 = Izadi | first3 = Hooshang | authorlink3 = | date = Aug 2019 | title = A retrospective outcome study of 42 patients with Chronic Fatigue Syndrome, 30 of whom had Irritable Bowel Syndrome. Half were treated with oral approaches, and half were treated with Faecal Microbiome Transplantation | url =https://linkinghub.elsevier.com/retrieve/pii/S2452231719300077|journal=Human Microbiome Journal|language=en|volume=13|issue= | pages = 100061|doi=10.1016/j.humic.2019.100061|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [https://www.sciencedirect.com/science/article/pii/S2452231719300077#t0010 (Full text)] *2019, Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome<ref>{{Cite journal | last = Wang | first = Yao | author-link = | last2 = Zheng | first2 = Fengling | authorlink2 = | last3 = Liu | first3 = Shan | authorlink3 = | last4 = Luo | first4 = Huanhuan | authorlink4 = | date = Dec 2019 | title = Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome | url =https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6914991/#!po=45.0000|journal=Gastroenterol Research and Practice|language=en|volume=|issue=| pages=|doi=10.1155/2019/9759138|pmc=|pmid=31885549|access-date=|quote=|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6914991/#!po=45.0000 (Full text)] ==See also== *[[Microbiome]] *[[Irritable bowel syndrome]] ==Learn more== *[https://quadram.ac.uk/wp-content/uploads/2020/02/ME-Public-Event-2020-all-slides-v8-final-for-website.pdf Gut Microbes, FMT and ME - slides by Simon Carding] [https://vimeo.com/391938608 Video] - RESTORE-ME study *[http://www.investinme.org/ce-proj3.shtml FMT Clinical Trial] - Invest in ME Research, Oct 8, 2019 *[https://designershitdocumentary.com/ Designer Shit] – a documentary about FMT scheduled for release sometime in 2019 *[http://www.drmyhill.co.uk/drmyhill/images/4/49/Home_Infusion_protocol.pdf Home Infusion Protocol] published by [[Sarah Myhill]] *[https://www.idsociety.org/FMT/ Infectious Diseases Society of America Information about FDA regulations re: FMT] *[http://thefecaltransplantfoundation.org/what-is-fecal-transplant/ The Fecal Transplant Foundation] *24 Aug 2019, [http://simmaronresearch.com/2019/08/fecal-transplant-chronic-fatigue-study-promise/ The First ME/CFS Fecal Transplant Study Suggests the Treatment Holds Promise] by [[Cort Johnson]] for [[Simmaron Research]] ==References== {{Reflist}} [[Category:Potential treatments]] [[Category:Probiotics]] [[Category:Digestive system]] [[Category:Blood, plasma or transplant treatments]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Templates used on this page:
Template:Cite journal
(
edit
)
Template:Cite web
(
edit
)
Template:Main other
(
edit
)
Template:Reflist
(
edit
)
Module:Check for unknown parameters
(
edit
)
Module:Citation/CS1
(
edit
)
Module:Citation/CS1/COinS
(
edit
)
Module:Citation/CS1/Configuration
(
edit
)
Module:Citation/CS1/Date validation
(
edit
)
Module:Citation/CS1/Identifiers
(
edit
)
Module:Citation/CS1/Utilities
(
edit
)
Module:Citation/CS1/Whitelist
(
edit
)
Module:No globals
(
edit
)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs